What Are the Most Important Compliance Concerns Regarding GLP1s?
- Jessica Zeff
- Jul 6
- 3 min read
The demand for GLP-1 medications continues to grow, and with that growth comes a new set of operational and regulatory challenges for healthcare organizations. While much of the public conversation centers on patient access and clinical outcomes, compliance professionals are spending more time evaluating the compliance concerns regarding GLP-1s that can affect prescribing practices, documentation, reimbursement, marketing, and organizational oversight.
The reality is that many of these risks are not tied to the medication itself. They develop when organizations scale services quickly, adopt new technology, or implement workflows without fully considering how regulatory requirements fit into day-to-day operations. From a compliance standpoint, the goal is to build processes that support appropriate patient care while reducing unnecessary risk for providers, staff, and the organization.
Telehealth Workflows Require More Than Convenience
Telehealth has expanded access to GLP-1 medications, but organizations should carefully evaluate how patients move through the prescribing process. The method of care delivery has a direct impact on documentation quality, patient safety, and regulatory compliance.
Questions worth asking include:
Does every patient receive an appropriate clinical evaluation before a prescription is issued?
Is the provider licensed in the patient's state?
How is patient identity verified?
Does the documentation support medical necessity?
Have potential risks, side effects, and treatment expectations been discussed with the patient?
On paper this may sound straightforward, but operationally, these conversations become more challenging when organizations rely heavily on asynchronous intake forms or automated workflows. Technology can improve efficiency, but it should never replace clinical judgment or meaningful provider involvement.
Compounded GLP-1 Medications Create Additional Compliance Considerations
As demand has increased and supply shortages have affected availability, more organizations have explored compounded GLP-1 medications to meet patient needs. What organizations often overlook is that compounding carries its own regulatory considerations, particularly when marketing materials or patient communications suggest that compounded products are equivalent to FDA-approved medications.
This becomes especially important in organizations where multiple departments contribute to patient communications. Compliance teams should work proactively with internal stakeholders to ensure messaging remains accurate and supported by current regulatory expectations.
Regular collaboration should include:
Marketing and communications
Clinical leadership
Pharmacy partners
Legal counsel
Operations teams
These reviews help reduce compliance exposure while supporting consistent messaging across the organization.
Documentation and Prior Authorization Remain Critical
The compliance concerns regarding GLP-1s also extend into reimbursement and utilization management. Because these medications represent a significant financial investment for both payers and patients, prior authorization requirements have become increasingly common, making documentation of medical necessity more important than ever.
In practice, organizations sometimes encounter situations where documentation is incomplete, diagnoses are coded inconsistently, or clinical records fail to demonstrate why the medication is appropriate for a particular patient. These issues often stem from workflow challenges rather than intentional misconduct, but they can still lead to payment denials, audit findings, and increased regulatory scrutiny.
Organizations should routinely evaluate whether their documentation processes support:
Medical necessity requirements
Complete patient histories
Appropriate diagnosis coding
Consistent clinical documentation
Accurate prior authorization submissions
Strong documentation protects both patients and organizations by supporting clinical decision-making and demonstrating compliance during audits.
Monitoring Fraud, Waste, and Abuse Risks
High demand for GLP-1 medications creates an environment where financial incentives, prescribing trends, and operational pressures can influence decision-making in ways that deserve careful oversight. This is where organizations can get into trouble when monitoring activities fail to keep pace with changing prescribing patterns.
Areas that deserve ongoing review include:
Prescribing patterns that differ significantly from peers
Unusual refill activity
Provider compensation structures tied to prescription volume
Refund policies that could unintentionally encourage unnecessary prescribing
Relationships with manufacturers, pharmacies, or third-party vendors
These reviews help identify trends before they become larger compliance concerns. They also provide leadership with meaningful information that supports continuous improvement instead of reactive problem solving.
Compliance Requires Cross-Functional Collaboration
A lot of organizations struggle with viewing GLP-1 oversight as a stand-alone initiative. The reality is that the compliance concerns regarding GLP-1s intersect with existing compliance programs, quality initiatives, clinical governance, privacy considerations, and enterprise risk management.
Effective oversight depends on collaboration across compliance, operations, clinical teams, legal counsel, pharmacy, IT, and executive leadership. The goal is not just to have a policy on paper. The goal is to develop workflows that consistently support appropriate prescribing, accurate documentation, transparent communication, and sound operational decision-making as regulatory expectations continue to evolve.
Organizations that build compliance into everyday operations are better positioned to adapt as guidance changes and patient demand continues to grow. Maintaining that balance between operational efficiency, patient access, and regulatory accountability is what strengthens both compliance programs and long-term organizational success.
Comments